Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME.TO)

Zymeworks Inc (ZYME.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zymeworks Inc 1385 West 8th Avenue Suite 540 Vancouver BC V6H 3V9 CAN

P: 604-678-1388

Description:

Zymeworks Inc is a clinical-stage company. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.

Key Statistics

Overview:

Market Capitalization, $K 1,299,504
Shares Outstanding, K 39,260
Annual Sales, $ 0 K
Annual Net Income, $ 0 K
% of Institutional Shareholders 75.23%

Growth:

1-Year Return 67.94%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 32.16%

Per-Share Information:

Latest Earnings Date 11/05/19
Earnings Per Share ttm -1.55
Dividend Payout Ratio 0.00%

ZYME.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -55.08%
Return-on-Assets % -39.83%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 2.94
Book Value/Share N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar